Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Kwon, Ji H ^a,b   Kim, Yu J ^a   Lee, Keun Wook ^a   Oh, Do Youn ^b   Park, So Y ^a   Kim, Jee H ^a   Chie, Eui K ^b   Kim, Sung Won ^a   Im, Seock Ah ^b   Kim, In Ah ^a   Kim, Tae You ^b   Park, In A ^b   Noh, Dong Young ^b   Bang, Yung Jue ^b   Ha, Sung W ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PROTEIN P53; TRASTUZUMAB; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGE; AGED; ARTICLE; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; RETROSPECTIVE STUDY; SURVIVAL RATE; BIOSYNTHESIS; BREAST TUMOR; GENE EXPRESSION REGULATION; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PROSPECTIVE STUDY; RECURRENT DISEASE; REGISTER; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77957924786     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-557     Document Type: Article

References (34)

1. Otto SJ, Fracheboud J, Looman CW, Broeders MJ, Boer R, Hendriks JH, Verbeek AL, de Koning HJ. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 2003, 361(9367):1411-1417. 10.1016/S0140-6736(03)13132-7, 12727393.
2. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353(17):1784-1792. 10.1056/NEJMoa050518, 16251534.
3. Duijm LE, Groenewoud JH, Roumen RM, de Koning HJ, Plaisier ML, Fracheboud J. A decade of breast cancer screening in The Netherlands: trends in the preoperative diagnosis of breast cancer. Breast Cancer Res Treat 2007, 106(1):113-119. 10.1007/s10549-006-9468-5, 17219049.
4. Son BH, Kwak BS, Kim JK, Kim HJ, Hong SJ, Lee JS, Hwang UK, Yoon HS, Ahn SH. Changing patterns in the clinical characteristics of Korean patients with breast cancer during the last 15 years. Arch Surg 2006, 141(2):155-160. 10.1001/archsurg.141.2.155, 16490892.
5. Ahn SH. Clinical characteristics of breast cancer patients in Korea in 2000. Arch Surg 2004, 139(1):27-30. discussion 31, 10.1001/archsurg.139.1.27, 14718270.
6. Joensuu H, Pylkkanen L, Toikkanen S. Late mortality from pT1N0M0 breast carcinoma. Cancer 1999, 85(10):2183-2189. 10.1002/(SICI)1097-0142(19990515)85:10<2183::AID-CNCR12>3.0.CO;2-K, 10326696.
7. Cavaliere A, Scheibel M, Bellezza G, Colella R, Vitali R, Gori S, Aristei C, Rulli A, Sidoni A. Ductal carcinoma in situ with microinvasion: clinicopathologic study and biopathologic profile. Pathol Res Pract 2006, 202(3):131-135. 10.1016/j.prp.2006.01.001, 16459026.
8. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 2007, 25(31):4952-4960. 10.1200/JCO.2006.08.0499, 17971593.
9. Fisher B, Dignam J, Tan-Chiu E, Anderson S, Fisher ER, Wittliff JL, Wolmark N. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 2001, 93(2):112-120. 10.1093/jnci/93.2.112, 11208880.
10. Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004, 22(9):1630-1637. 10.1200/JCO.2004.09.070, 15117985.
11. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008, 107(3):309-330. 10.1007/s10549-007-9556-1, 2217620, 17377838.
12. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Viale G, Renne G, Casadio C, Veronesi P, Intra M, Torrisi R, et al. Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. Ann Oncol 2004, 15(11):1633-1639. 10.1093/annonc/mdh434, 15520064.
13. Choi DH, Shin DB, Lee MH, Lee DW, Dhandapani D, Carter D, King BL, Haffty BG. A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer 2003, 98(8):1587-1595. 10.1002/cncr.11703, 14534873.
14. Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg 2007, 31(5):1031-1040. 10.1007/s00268-005-0585-9, 17387549.
15. Cancer AJCo AJCC Cancer Staging Manual. 2002, New York, NY: Springer, 6, Cancer AJCo.
16. Jung SY, Han W, Lee JW, Ko E, Kim E, Yu JH, Moon HG, Park IA, Oh DY, Im SA, et al. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol 2009, 16(5):1112-1121. 10.1245/s10434-009-0334-7, 19219507.
17. Stierer M, Rosen HR, Weber R, Marczell A, Kornek GV, Czerwenka E. Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter. Surg Gynecol Obstet 1992, 175(2):151-160.
18. Leitner SP, Swern AS, Weinberger D, Duncan LJ, Hutter RV. Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0). Cancer 1995, 76(11):2266-2274. 10.1002/1097-0142(19951201)76:11<2266::AID-CNCR2820761114>3.0.CO;2-T, 8635031.
19. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkanen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003, 9(3):923-930.
20. Trudeau ME, Pritchard KI, Chapman JA, Hanna WM, Kahn HJ, Murray D, Sawka CA, Mobbs BG, Andrulis I, McCready DR, et al. Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Res Treat 2005, 89(1):35-45. 10.1007/s10549-004-1368-y, 15666195.
21. Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S. Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol 1995, 13(5):1144-1151.
22. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Orlando L, Ghisini R, Viale G, Pruneri G, Veronesi P, Luini A, et al. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol 2006, 17(10):1497-1503. 10.1093/annonc/mdl145, 16798834.
23. Ponzone R, Montemurro F, Maggiorotto F, Robba C, Gregori D, Jacomuzzi ME, Kubatzki F, Marenco D, Dominguez A, Biglia N, et al. Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. Ann Oncol 2006, 17(11):1631-1636. 10.1093/annonc/mdl296, 16980602.
24. Railo M, Lundin J, Haglund C, von Smitten K, Nordling S. Ki-67, p53, ER receptors, ploidy and S phase as long-term prognostic factors in T1 node-negative breast cancer. Tumour Biol 2007, 28(1):45-51. 10.1159/000097702, 17143016.
25. Rakkhit RBK, Peintinger F, Cardoso F, Hanrahan EO, Litton JK, Sahin A, Larsimont D, Meric-Bernstam F, Buchholz TA, Valero V, Theriault RL, Piccart M, Ravdin P, Hortobagyi GN, Gonzalez-Angulo AM. Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. Abstract. The 31th CTRC-AACR San Antonio Breast Cancer Symposium 2008,
26. Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, Han W. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. J Clin Oncol 2007, 25(17):2360-2368. 10.1200/JCO.2006.10.3754, 17515570.
27. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997, 47(1):5-27. 10.3322/canjclin.47.1.5, 8996076.
28. Tovey SM, Brown S, Doughty JC, Mallon EA, Cooke TG, Edwards J. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer 2009, 100(5):680-683. 10.1038/sj.bjc.6604940, 2653773, 19223897.
29. Torrisi R, Rotmensz N, Bagnardi V, Viale G, Curto BD, Dell'orto P, Veronesi P, Luini A, D'Alessandro C, Cardillo A, et al. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 2007, 43(16):2339-2344. 10.1016/j.ejca.2007.07.033, 17855075.
30. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 16(3):876-887. 10.1158/1078-0432.CCR-09-1532, 20103682.
31. Menard S, Balsari A, Tagliabue E, Camerini T, Casalini P, Bufalino R, Castiglioni F, Carcangiu ML, Gloghini A, Scalone S, et al. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Ann Oncol 2008, 19(10):1706-1712. 10.1093/annonc/mdn369, 18544559.
32. Louwman WJ, van Beek MW, Schapers RF, Nolthenius-Puylaert MB, van Diest PJ, Roumen RM, Coebergh JW. Long-term survival of T1 and T2 lymph node-negative breast cancer patients according to Mitotic Activity Index: a population-based study. Int J Cancer 2006, 118(9):2310-2314. 10.1002/ijc.21623, 16331599.
33. Baak JP, van Diest PJ, Janssen EA, Gudlaugsson E, Voorhorst FJ, van der Wall E, Vermorken JB. Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. Ann Oncol 2008, 19(4):649-654. 10.1093/annonc/mdm535, 18042836.
34. Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009, 27(8):1168-1176. 10.1200/JCO.2008.18.1024, 2667821, 19204205.